Nephrocare Health Services Intrinsic Value
Nephrocare Health Services (NEPHROPLUS) median intrinsic value is ₹1535.25 from 4 valuation models (range ₹1228–₹1535), vs current price ₹614.10 — +150.0% upside (Trading Below Calculated Value), margin of safety 60.0%. Also explore NEPHROPLUS share price charts to track price trends across different timeframes.
NEPHROPLUS Valuation Methods Summary — DCF, Graham Number & P/E
Nephrocare Health Services intrinsic value across 4 models vs current price ₹614.10 — upside/downside and value range per method. Browse NEPHROPLUS complete financial statements for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹1535.25 | ₹1381.73 - ₹1688.78 | +150.0% | Book Value/Share: ₹2920.00, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹1228.20 | ₹1105.38 - ₹1351.02 | +100.0% | Revenue/Share: ₹5000.00, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹1228.20 | ₹1105.38 - ₹1351.02 | +100.0% | EBITDA: ₹272.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹1535.25 | ₹1228.20 - ₹1842.30 | +150.0% | CF Growth: 15.0%, Discount: 15% |
NEPHROPLUS Intrinsic Value vs Market Price — All Valuation Models
Nephrocare Health Services fair value range ₹1228–₹1535 vs current market price ₹614.10 across 4 valuation models. For current market price and key ratios, visit Nephrocare Health Services share price screener.
NEPHROPLUS Intrinsic Value Analysis — Undervalued or Overvalued?
Nephrocare Health Services median intrinsic value ₹1535.25, current price ₹614.10 — Trading Below Calculated Value by 150.0%, margin of safety 60.0%.
What is the intrinsic value of NEPHROPLUS?
Based on our comprehensive analysis using 4 different valuation methods, the estimated intrinsic value of Nephrocare Health Services (NEPHROPLUS) is ₹1535.25 (median value). With the current market price of ₹614.10, this represents a +150.0% variance from our estimated fair value.
The valuation range spans from ₹1228.20 to ₹1535.25, indicating ₹1228.20 - ₹1535.25.
Is NEPHROPLUS undervalued or overvalued?
Based on our multi-method analysis, Nephrocare Health Services (NEPHROPLUS) appears to be trading below calculated value by approximately 150.0%.
NEPHROPLUS Financial Health — Key Ratios vs Industry Benchmarks
Nephrocare Health Services financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 4.22 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | -6.8% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 26.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.00x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
NEPHROPLUS Cash Flow Quality — Operating & Free Cash Flow
Nephrocare Health Services operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹135 Cr | ₹73 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹72 Cr | ₹46 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹11 Cr | ₹-27 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹14 Cr | ₹-51 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹32 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |